Author pages are created from data sourced from our academic publisher partnerships and public sources.
Anticancer activity for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogues and their abilities to interact with lymphoendothelial cell surface markers.
- L. Morgan, B. S. Jursic, C. Hooper, D. Neumann, K. Thangaraj, Blaise Leblanc
- Chemistry, Medicine
- Bioorganic & medicinal chemistry letters
- 2 December 2002
The structure of the anticancer agent 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) has been modified through SAR and by incorporating barbituric acid, pyridine, quinoline, and… Expand
Inhibition of DNA synthesis in Harding-Passey melanoma cells by prostaglandins A1 and A2: comparison with chemotherapeutic agents.
- K. Honn, J. R. Dunn, L. Morgan, M. Bienkowski, L. Marnett
- Biology, Medicine
- Biochemical and biophysical research…
- 13 April 1979
Abstract PGA 1 and PGA 2 significantly depressed melanoma cell DNA synthesis and cell proliferation in a dose related fashion. Inhibition of DNA synthesis was rapid in onset (0.5–1 hr) and sustained… Expand
Relationship of oxygen consumption and cytochrome oxidase-succinic dehydrogenase activities in the Amphiuma means
Abstract 1. 1. Oxygen consumption of intact Amphiuma means were measured and compared with their liver succinie dehydrogenase and cytochrome oxidase activities. 2. 2. A parabolic relationship exists… Expand
Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development.
Charge is an important characteristic of drug molecules, since ionization sites determine the pKa at a particular pH. The pKa in turn can affect many parameters, including solubility, dissolution… Expand
Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide
- N. Germann, S. Urien, +7 authors L. Morgan
- Cancer Chemotherapy and Pharmacology
- 1 February 2005
BackgroundIsophosphoramide mustard (IPM) is the cytotoxic alkylating metabolite of Ifosfamide (IFOS). IPM is being readied for a phase I clinical trial. In the present preclinical study, IPM was… Expand
N-acetylcysteine: its bioavailability and interaction with ifosfamide metabolites.
Comparative preclinical toxicology and pharmacology of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in vitro and in rodents and primates.
4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) is being evaluated for its anticancer activities. Acute, subacute and chronic oral, dermal, opthalmic and dermal LD50 and acceptance… Expand
Comparative dermal pharmacology and toxicology of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in rodents and primates.
4,4'-Dihydroxybenzophenone-2,4-ditrophenylhydrazone (A-007) has demonstrated anticancer activities, when administered topically to patients with metastatic cancer to the skin. Acute, subacute and… Expand
Arylsulfatase B in colorectal cancer
Arylsulfatase B activity has been determined in 24‐hour urine samples from 243 patients with colorectal cancer. Elevated activity of the enzyme was observed in 172 out of 243 (71%) patients.… Expand
Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.
Tamoxifen (NSC-180973; ICI-46474) can provide palliation to patients with advanced breast cancer whose tumors contain estrogen-binding proteins (EBP). The drug is most effective in patients with bone… Expand